Welcome to our dedicated page for Scinai Immunotherapeutics Ltd. news (Ticker: SCNI), a resource for investors and traders seeking the latest updates and insights on Scinai Immunotherapeutics Ltd. stock.
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) maintains an active pipeline of inflammation and immunology therapies while providing specialized CDMO services through its biosolutions division. This news hub aggregates official announcements, clinical trial updates, and strategic developments for stakeholders tracking the company's progress in biologic therapeutics.
Investors and industry professionals will find verified updates on NanoAb platform advancements, manufacturing capabilities, and partnership announcements. The curated collection includes earnings reports, regulatory filings, and scientific milestone disclosures - all sourced directly from company communications.
Key content categories include clinical trial phases, intellectual property developments, bioservices expansions, and executive leadership updates. Each entry maintains timestamped accuracy while focusing on material business developments relevant to therapeutic innovation and CDMO operations.
For consistent access to primary-source information about Scinai's dual-focused biopharmaceutical strategy, bookmark this page or configure news alerts through your Stock Titan account. Ensure informed decision-making with comprehensive updates on both therapeutic pipeline progress and contract manufacturing service enhancements.
Scinai Immunotherapeutics has released its financial results for FY 2023, reporting a net loss of $6.5 million, an increase from $5.8 million in 2022. The company raised $1.69 million in January 2024 through warrant exercises and secured a grant from the Israel Innovation Authority covering 66% of a CDMO project. Scinai's CDMO unit reported $500K in work orders for early 2024, projecting $1.25 million in revenue for the year. In its pipeline, Scinai highlighted positive preclinical results for its anti-IL-17 NanoAbs for psoriasis and ongoing strategic partnerships for COVID-19 treatments. The company also saw a decrease in R&D and administrative expenses but reported lower financial income and reduced cash reserves of $4.9 million as of December 31, 2023.
Scinai Immunotherapeutics (Nasdaq: SCNI) has received a delisting notification from Nasdaq due to non-compliance with the minimum $1.00 bid price requirement. The company is appealing the determination and has approved a ratio change of its ADSs to non-traded ordinary shares, equivalent to a reverse split, to regain compliance. No action is required by the ADS holders for the ratio change, which is expected to be effective on May 21, 2024.
FAQ
What is the current stock price of Scinai Immunotherapeutics Ltd. (SCNI)?
What is the market cap of Scinai Immunotherapeutics Ltd. (SCNI)?
